Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Tate

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Pain|June 29, 2012
Nav(1.8)igating the maze of sensory functionSimon Tate, Dominique Derjean, François Rugiero
Nature Reviews. Drug Discovery|January 1, 2009
Transient receptor potential channels: targeting pain at the sourceArdem Patapoutian, Simon Tate, Clifford J Woolf
Neuroscience Letters|January 20, 2004
Differential expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 in normal and inflamed ratsRichard E Coggeshall, Simon Tate, Susan M Carlton
Current Opinion in Pharmacology|February 26, 2014
Multiple mechanisms have been tested in pain--how can we improve the chances of success?Ann G Hayes, Lars Arendt-Nielsen, Simon Tate
Pain|April 26, 2002
The pattern of expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain modelsIsabelle Decosterd, Ru-Rong Ji, Salahadin Abdi, et al.
Molecular and Cellular Neurosciences|October 11, 2003
High basal expression and injury-induced down regulation of two regulator of G-protein signaling transcripts, RGS3 and RGS4 in primary sensory neuronsMichael Costigan, Tarek A Samad, Andrew Allchorne, et al.
Journal of Pain Research|July 17, 2020
Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal NeuralgiaMona Kotecha, William P Cheshire, Helen Finnigan, et al.
Trials|November 26, 2013
Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgiaJoanna M Zakrzewska, Joanne Palmer, Dominik A Ettlin, et al.
Molecular Medicine (Cambridge, Mass.)|August 7, 2016
A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgiaBrian S Tanaka, Peng Zhao, Fadia B Dib-Hajj, et al.
Clinical Pharmacology in Drug Development|October 26, 2019
Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy VolunteersJoi Dunbar, Mark Versavel, Yuan Zhao, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Pain|June 29, 2012
Nav(1.8)igating the maze of sensory functionSimon Tate, Dominique Derjean, François Rugiero
Nature Reviews. Drug Discovery|January 1, 2009
Transient receptor potential channels: targeting pain at the sourceArdem Patapoutian, Simon Tate, Clifford J Woolf
Neuroscience Letters|January 20, 2004
Differential expression of tetrodotoxin-resistant sodium channels Nav1.8 and Nav1.9 in normal and inflamed ratsRichard E Coggeshall, Simon Tate, Susan M Carlton
Current Opinion in Pharmacology|February 26, 2014
Multiple mechanisms have been tested in pain--how can we improve the chances of success?Ann G Hayes, Lars Arendt-Nielsen, Simon Tate
Pain|April 26, 2002
The pattern of expression of the voltage-gated sodium channels Na(v)1.8 and Na(v)1.9 does not change in uninjured primary sensory neurons in experimental neuropathic pain modelsIsabelle Decosterd, Ru-Rong Ji, Salahadin Abdi, et al.
Molecular and Cellular Neurosciences|October 11, 2003
High basal expression and injury-induced down regulation of two regulator of G-protein signaling transcripts, RGS3 and RGS4 in primary sensory neuronsMichael Costigan, Tarek A Samad, Andrew Allchorne, et al.
Journal of Pain Research|July 17, 2020
Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal NeuralgiaMona Kotecha, William P Cheshire, Helen Finnigan, et al.
Trials|November 26, 2013
Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgiaJoanna M Zakrzewska, Joanne Palmer, Dominik A Ettlin, et al.
Molecular Medicine (Cambridge, Mass.)|August 7, 2016
A gain-of-function mutation in Nav1.6 in a case of trigeminal neuralgiaBrian S Tanaka, Peng Zhao, Fadia B Dib-Hajj, et al.
Clinical Pharmacology in Drug Development|October 26, 2019
Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy VolunteersJoi Dunbar, Mark Versavel, Yuan Zhao, et al.
Pageof 2